Introduction
Progress in the development of treatments for cancer remains slow; thus, alternative strategies for drug development such as repurposing previously approved drugs are being considered (Pasquier et al., 2011) . This strategy may reduce risks, costs and time required in drug development (Pasquier et al. 2011) . A specific example of this is the potential antineoplastic effect of aspirin, with a near 50% reduction in cancer-specific mortality from colorectal cancer recently shown in those starting aspirin after diagnosis (Chan et al., 2009) , which has already led to a randomized controlled trial (Ali et al., 2011) .
Laboratory studies have shown that, by blocking adrenergic signalling, both β-blockers and α-blockers inhibit stimulation of growth and migratory activity of tumour cells by these neurotransmitters (Masur et al., 2001; Benning and Kyprianou, 2002; Drell et al., 2003; Foster et al., 2004; Lang et al., 2004; Palm et al., 2006; Sood et al., 2006; Hui et al., 2008; Al-Wadei et al., 2009; Sakamoto et al., 2011; Pasquier et al., 2013) . Furthermore, β-blockade has proven efficacy in the treatment of infantile haemangiomas (Fuchsmann et al., 2011; Xu et al., 2012) .
These encouraging results have led to a number of epidemiological studies on β-blockers, which have not shown a consistent beneficial effect in common cancers (González-Pérez et al., 2004; Perron et al., 2004; Ronquist et al., 2004; Algazi et al., 2006; Rodriguez et al., 2009; Friedman et al., 2011; Hallas et al., 2012; Jansen et al., 2012) . Few epidemiological studies have been undertaken on α-blockers, and the evidence available is inconsistent (Friedman et al., 2011; Hallas et al., 2012) .
Limited sample sizes and inadequate adjustment for confounders in some studies have possibly contributed to the differences observed in the results. To address this problem, we conducted a case-control study using data from the Clinical Practice Research Datalink (CPRD) database, a large population healthcare database that allows adjustment for relevant confounding variables. We investigated the four most common cancers in the UK: colorectal, lung, breast and prostate cancer (Office for National Statistics, 2012), as laboratory studies have Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's website (www.eurjcancerprev.com).
shown evidence of an antitumourigenic effect of adrenergic blockers on them (Schuller and Cole, 1989; Masur et al., 2001; Drell et al., 2003) , and CPRD provided adequate power to investigate each. In addition, we have investigated the effect of differing doses and durations of adrenergic blockers and the specificity of their effect by comparing the results obtained with those obtained from another class of agents sharing a number of their indications (calcium-channel blockers).
Materials and methods

Setting
The CPRD contains anonymized computerized clinical information from over 600 general practices across the UK, with the earliest records dating back to 1987. These records include more than 11 million patients (Card et al., 2014) , making it the largest source of anonymized longitudinal data from primary care in the world (Khan et al., 2010) . Individual records include demographic information, clinical diagnoses and prescription and treatment details.
Study population
We conducted a frequency-matched case-control study of patients during the period in which they contributed prospectively gathered data to CPRD from the period between 1 January 1987 and 31 December 2012, occurring after the age of 18 years and at least 2 years after they entered the dataset. Cases were defined by a firstrecorded medical diagnosis of lung, bowel, prostate or breast cancer. Controls were selected from among contributing participants with no recorded medical diagnosis of prostate, lung, bowel or breast cancer in their clinical record before a random date allocated (henceforth referred to as their pseudodiagnosis date) and were frequency matched by 10-year age bands in a ratio of 10 : 1 for each malignancy separately. In addition, we limited control selection for breast cancer to females and for prostate cancer to males.
Exposure and covariates
Participants with two or more prescriptions for α-or β-blockers within the 2-year window before diagnosis or pseudodiagnosis were considered exposed. We then considered dose by determining the mean dose across all exposed days for each participant and dividing it by the maximum recommended daily dose [of the individual adrenergic blocker used, as determined by the British National Formulary (BNF)]. We used the median of the standardized doses across a combination of cancers under study to categorize participants into high-dose, low-dose and unexposed categories.
Age and sex were considered as a-priori confounders. Other potential confounders considered include smoking, alcohol use, comorbidity (using the Charlson comorbidity index as a composite measure (Charlson et al., 1987) , prophylactic medications (NSAID, statin and aspirin), hormone replacement therapy and potential indications for the use of the medications studied including ischaemic heart disease, heart failure, hypertension, history of diabetes and benign prostatic hyperplasia and/or prostatism. Medication use was defined as two or more prescriptions for the specific medication within the 2-year window before diagnosis or pseudodiagnosis. Comorbidity and indication for use of the drug were assessed as any recordings of the variable before the date of diagnosis or pseudodiagnosis. The Charlson index is a composite score of comorbidities categorized as none, 1 and 2. Age was calculated at the date of diagnosis or pseudodiagnosis, whereas BMI, smoking status and alcohol status were measured as the most recent recording of the variables before the date of diagnosis or pseudodiagnosis. Smoking status was categorized as nonsmoker, current smoker, ex-smoker or missing; alcohol status as nondrinker, current drinker, problemdrinker or missing; and BMI into five categories, including missing. We created a missing category for all variables with missing data.
Data analysis
We analysed the data using univariate and subsequently multivariate logistic regression analyses for each cancer under study, with the resulting odds ratios (ORs) and 95% confidence intervals (CIs) presented. Among the variables. We extracted data for these based on the plausibility of their confounding the relationship being studied. We determined potential confounders based on their association with the exposure and the outcome and corroborated these by similar studies conducted in this area. We built the multivariable model by first including all possible confounders in the model and progressively removing confounders one at a time from the model, in increasing order of importance, that did not change the estimate of the effect of the primary exposure by at least 10%. We did this until none of the variables retained in the model could be removed without altering the effect estimate of the model significantly. At the end of each step of fitting the model, we repeated this process, but instead, we progressively added confounders one at a time to the model, in decreasing order of importance, to determine whether the included confounders remained significant in the model and whether the removed confounders became significant in the model. We did this until we had only significant confounders present in the model.
Sensitivity analysis
We assessed the effect of duration of adrenergic blocker use within a 10-year window before diagnosis or pseudodiagnosis in a subset of participants with 10 years of prospectively gathered data. We assessed the number of years of exposure of a participant, starting from the date of the participant's diagnosis or the pseudodiagnosis date Table 1 Lifestyle factors and indications for use of adrenergic blockers for cases and controls BPH, benign prostatic hyperplasia; IHD, ischaemic heart disease.
until the participant's their earliest exposure within this 10-year window. Participants were considered to have been exposed for the years during which they had at least one relevant prescription, and continuous exposure was considered to have occurred for the number of consecutive years during which they were exposed, counting backwards from the date of diagnosis or pseudodiagnosis.
Further analysis
Finally, we repeated all analyses substituting calciumchannel blockers as the exposure. All analyses were carried out in using Stata 12 (Stata Corp., College Station, Texas, USA).
Results
We Cancer patients were more likely to be current drinkers, and had more comorbidities and a higher incidence of hypertension than their respective controls (Table 1 ). In addition, lung cancer patients comprised more current and ex-smokers and had a higher level of aspirin and statin use compared with controls. There was also a smaller proportion of missing data on smoking status, alcohol status and BMI among patients compared with controls for all cancers (Table 1 ). All other variables were similarly distributed among cases and controls.
Cancer patients showed more adrenergic blocker use than controls (Table 2) . Univariate analysis showed a significant positive association between α-and β-blocker exposure and all cancers ( 
Analysis by dose
We found no clear evidence of differences in cancer risk with variations in dose. Although point estimates did vary by dose, changes were small and CIs overlapped. Further details of adrenergic blocker use by dose are shown below (Table 3) .
Analysis of duration in those with prolonged data
We found no significant effect on cancer risk from regular long-term adrenergic blocker use in the subset of patients with more prolonged data availability (Table 4) .
Discussion
In this large case-control study, we found no effect of β-blocker exposure over the 2-year period before cancer diagnosis on the risk of lung or prostate cancer, and we found a slight increase in the risk of colorectal and breast cancers. α-Blocker exposure showed no effect on the risk of breast and prostate cancers and a slight increase in the risk of colorectal cancer. Analysis by dose and long-term exposure showed no clear dose or temporal effect on cancer risk for adrenergic blocker use.
Study strengths and limitations
This study is from a large primary-care database representative of the UK population (Herrett et al., 2010) and, as data collection within the CPRD is prospective, information bias due to recall will be minimized. In addition, we were able to adjust for a number of important confounders including alcohol status, smoking status, BMI, medication use and comorbidities.
A major limitation is our inability to individually validate cancer diagnoses and a potential, therefore, for misclassification. However, given the previously demonstrated high levels of specificity for diagnoses in these data -that is, 99% of neoplasms (Dregan et al., 2012) -we do not believe that this will have greatly influenced our study.
Our analyses confirm the presence of appreciable confounding in the relationships that we have studied; however, as we lack data on some potential confounders such as family history, diet and exercise, it is likely that residual confounding will remain.
Another potential limitation is missing data for confounding factors, including both over-the-counter medication use (primarily NSAIDS and aspirin) and lifestyle factors, with a smaller proportion of missing data observed for smoking status, alcohol status and BMI among cases compared with controls. It is likely that these data are not missing at random but are missing because of variations in medical records as a consequence of variations in comorbidities or the frequency of physician visits. We have attempted to minimize this potential information bias by including 'missing' as a separate category in the analysis for alcohol use, smoking and BMI. However, the potential for some information bias and likelihood of residual confounding remain.
Another potential bias is the possibility that those who are prescribed antihypertensives are more likely to have an early diagnosis of cancer because of their increased contact with healthcare services. This bias cannot be entirely overcome, but as the same mechanism might be expected to increase the prescription of other drugs used for similar indications, we analysed calcium-channel blockers. The effects of calcium-channel blockers were similar to those of β-blockers, and as these have different mechanisms of action, it is unlikely that the results obtained for β-blocker use reflect the effect of the drug, but instead they suggest bias by healthcare-seeking behaviour.
Our primary analysis restricted the assessment of adrenergic blocker use to the presence of two prescriptions within 2 years. It is possible that these criteria did not adequately reflect exposure, as we have no data on adherence to treatment and the results could instead represent a low dose of adrenergic drug use. We therefore analysed the dose of adrenergic blocker use. As minimal effects were seen with varying dose, we do not think that these issues are likely to invalidate our primary analysis.
Furthermore, it is possible that the time window of 2 years represents insufficiently prolonged exposure to see a therapeutic effect on the occurrence of cancer, and a longer exposure period may be required. Therefore, we examined the effect of a longer duration of exposure in a subset of patients who had up to 10 years of data before the date of diagnosis or pseudodiagnosis. These results did not alter our effect estimates and, as a result, we believe that a longer duration of adrenergic blocker exposure does not have a greater effect on the risk of cancer.
Comparison with other studies
Previous studies have examined β-blocker use and the incidence of colorectal (Friedman et al., 2011; Jansen et al., 2012) , prostate (Perron et al., 2004; Ronquist et al., 2004; Rodriguez et al., 2009; Friedman et al., 2011 ), breast (González-Pérez et al., 2004 Fryzek et al., 2006; Friedman et al., 2011) , lung (Friedman et al., 2011) and all cancers (Algazi et al., 2006; Friedman et al., 2011; Hallas et al., 2012) .
Some studies, such as the matched case-control studies by Perron et al. (2004) , utilized large clinical databases, showing a reduced incidence of prostate cancer on β-blocker exposure [0.86 (0.77-0.96) ], but they only adjusted for the confounding factors of age, sex, aspirin use and recent medical contacts, which differed from the results of our study.
Other studies considered β-blocker use and cancer risk only in subgroup analyses, and it is likely that these studies were underpowered to detect significant effects (González-Pérez et al., 2004; Fryzek et al., 2006; Rodriguez et al., 2009) . For instance, a nested case-control study by González-Pérez et al. (2004) on antihypertensive use and breast cancer risk initially included 3708 cases and 20 000 controls; however, to examine adrenergic blocker use, the duration of use was split into current use, past use and no use, and this resulted in a population with a very small number of cases and controls for some levels of drug exposure. The results showed no statistically significant difference in breast cancer incidence between patients on β-and α-blockers and differ from the results of our study on β-blocker use (González-Pérez et al., 2004) .
The most convincing evidence from large populationbased studies was from a case-control study by Ronquist et al. (2004) that was conducted using the CPRD database. This study examined 1013 cases of prostate cancer and 10 000 controls, with adjustments for important confounders including smoking status, BMI and alcohol use. The results showed no statistically significant difference between β-blocker users and nonusers, with ORs of 0.8 (0.6-1.0) for current use and 1.1 (0.9-1.4) for past use compared with nonuse; for α-blocker use, ORs of 3.6 (2.8-4.6) for current use and 1.1 (0.8-1.7) for past use were obtained compared with nonuse. As we have used the same data source, although they used a larger and more recent version than in this study, it is reassuring that we found similar results. We have also, however, expanded upon this study by including cancers of the breast, bowel and lung, and within this, we investigated the dose and duration of use, as well as the indication for use, and can therefore provide more extensive information on the effect of adrenergic blocker exposure on the risk of cancer.
Interpretation
In this study, we found no effect in some cancers and a weakly positive association of adrenergic blockade in Adrenergic blockers and common cancer risk Numbere et al. 91
others, contrary to what might be expected on the basis of evidence from laboratory studies. It is possible that a higher concentration of adrenergic blockers than that prescribed for cardiovascular indications is needed to reproduce the proapoptotic effects observed in these laboratory models. In addition, several preclinical studies propose that downstream β-adrenergic effects are mediated mainly by the β2 or β3 adrenergic receptors (Laag et al., 2006; Thaker et al., 2006) . As β1-selective β-blockers are more commonly prescribed for cardiovascular therapy, we were unable to look at the nonselective β-blocker subgroup for a beneficial effect. However, the results are not strongly significant in any cancer under study, and it is possible that the slight increase in cancer risk observed in some cancers and the associated small effect sizes represent residual confounding because of the limited or lack of data on potential confounders such as family history, diet and exercise.
Conclusion
To our knowledge, this is the most comprehensive study to date on the effect of α-blocker and β-blocker use on the incidence of common cancers in the UK. We found no significant association between adrenergic blocker use and a reduced incidence of cancer, and our finding of no consistent dose-response or temporal relationship or specificity of effect (compared with calcium-channel blockers) could mean that it is more than likely that the slight increase in risk observed in some cancers is a result of residual confounding. However, an effect in specific β-blocker subgroups cannot be ruled out, and further epidemiological research will require even larger epidemiological studies or pooled data to produce statistically robust results. This study using a large population database does not provide support for the hypothesis that adrenergic blocker use is associated with a reduced incidence of cancer.
